Sutro Biopharma Inc
Company Profile
Business description
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
Contact
111 Oyster Point Boulevard
South San FranciscoCA94080
USAT: +1 650 881-6500
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
131
Stocks News & Analysis
stocks
What AI means for US software companies’ moats
stocks
Lower moat ratings on four ASX shares due to AI
stocks
What Q4 US earnings did and didn’t tell us about AI and the outlook for tech shares
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,733.70 | 106.80 | -1.21% |
| CAC 40 | 7,993.49 | 52.31 | -0.65% |
| DAX 40 | 23,591.03 | 224.72 | -0.94% |
| Dow JONES (US) | 47,501.55 | 453.19 | -0.95% |
| FTSE 100 | 10,284.75 | 129.19 | -1.24% |
| HKSE | 25,135.35 | 621.94 | -2.41% |
| NASDAQ | 22,387.68 | 361.31 | -1.59% |
| Nikkei 225 | 51,740.46 | 3,880.38 | -6.98% |
| NZX 50 Index | 13,087.37 | 530.52 | -3.90% |
| S&P 500 | 6,740.02 | 90.69 | -1.33% |
| S&P/ASX 200 | 8,509.80 | 92.50 | -1.08% |
| SSE Composite Index | 4,081.89 | 42.30 | -1.03% |